- Home
- ZIP vs SLN Comparison
ZIP vs SLN Comparison
Compare ZIP & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZIP | SLN |
|---|---|---|
| Founded | 2010 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.3M | 318.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZIP | SLN |
|---|---|---|
| Price | $5.31 | $6.98 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $4.88 | ★ $39.67 |
| AVG Volume (30 Days) | ★ 806.3K | 280.4K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $448,299,000.00 | $25,830,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.94 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 40.39 |
| 52 Week Low | $3.35 | $1.97 |
| 52 Week High | $8.56 | $8.88 |
Technical Indicators
Market Signals| Indicator | ZIP | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 66.19 | 56.90 |
| Support Level | $5.12 | $5.98 |
| Resistance Level | $4.84 | $6.88 |
| Average True Range (ATR) | 0.29 | 0.52 |
| MACD | 0.12 | 0.02 |
| Stochastic Oscillator | 86.05 | 71.63 |
Price Performance
Historical ComparisonAbout ZIP ZipRecruiter Inc.
ZipRecruiter Inc is an online employment marketplace. It connects millions of job seekers with companies of all sizes. It is a two-sided marketplace for work that simplifies the job market for both job seekers and employers. Unlike traditional online job sites, ZipRecruiter works like a matchmaker curating job opportunities for job seekers, and candidates for employers.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.